» Articles » PMID: 37978024

Prognosis of Gleason Score 9-10 Prostatic Adenocarcinoma in Needle Biopsies: A Nationwide Population-based Study

Overview
Journal Eur Urol Oncol
Specialties Oncology
Urology
Date 2023 Nov 17
PMID 37978024
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Since 2014, prostate cancer is reported using five-tier grouping of Gleason scores. Studies have suggested prognostic heterogeneity within the groups.

Objective: We assessed the risk of prostate cancer death for men diagnosed with Gleason scores 4 + 5, 5 + 4, and 5 + 5 on needle biopsy in a population-based cohort.

Design, Setting, And Participants: We used the data from Prostate Cancer data Base Sweden (PCBaSe) 4.0 for a survival analysis. Among 199 620 men reported to have prostate cancer in 2000-2020, 172 112 were diagnosed on needle biopsy. The primary treatment was classified as androgen deprivation therapy (66%), deferred treatment (5%), radical prostatectomy (7%), or radical radiotherapy (21%).

Outcome Measurements And Statistical Analysis: The risks of death from prostate cancer in men with Gleason score 9-10 at 5 and 10 yr were used as endpoints. Multivariable Cox regression models controlling for socioeconomic factors and primary treatment were used for time-to-event analyses of death from prostate cancer and death from any causes.

Results And Limitations: A total of 20 419 (12%) men had a Gleason score of 9-10, including Gleason scores of 4 + 5, 5 + 4, and 5 + 5 in 14 333 (70%), 4223 (21%), and 1863 (9%) men, respectively. The risks of prostate cancer death for men with Gleason scores 4 + 5, 5 + 4, and 5 + 5 at 10 yr of follow-up were 0.45 (confidence interval [CI] 0.44-0.46), 0.56 (0.55-0.58), and 0.66 (0.63-0.68), respectively. The risks of death of any cause for men with Gleason scores 4 + 5, 5 + 4, and 5 + 5 at 10 yr were 0.73 (CI 0.72-0.74), 0.81 (0.80-0.83), and 0.87 (0.85-0.89), respectively.

Conclusions: We demonstrate in the largest and most complete cohort analyzed to date that collapsing the Gleason scores by grouping results in loss of prognostic information in men with Gleason score 9-10 cancer.

Patient Summary: Survival of prostate cancer patients with the highest tumor grades varies depending on grade composition.

Citing Articles

Real-World Treatment Patterns and Survival Outcomes in Metastatic Hormone-Sensitive Prostate Cancer: Insights From a Retrospective Cohort Study.

Tashkandi E Cancer Manag Res. 2025; 17:419-428.

PMID: 40046653 PMC: 11881765. DOI: 10.2147/CMAR.S506423.


Clinical characteristics and survival of patients with de novo metastatic prostate cancer treated with androgen deprivation therapy and taxane-based chemotherapy in Uganda: a retrospective study.

Bakenga A, Natukunda B, Okuku F, Mubiru K, Kakungulu E, Kyagulanyi E BMC Cancer. 2024; 24(1):1404.

PMID: 39543506 PMC: 11566626. DOI: 10.1186/s12885-024-13147-z.


Patients ask and pathologists answer: ten questions around prostate cancer grading.

Cimadamore A, Cheng L, Lopez-Beltran A, Franzese C, Giannarini G, Crestani A Virchows Arch. 2024; .

PMID: 39153109 DOI: 10.1007/s00428-024-03891-9.


Prognosis of Gleason score 8 prostatic adenocarcinoma in needle biopsies: a nationwide population-based study.

Egevad L, Micoli C, Delahunt B, Samaratunga H, Orrason A, Garmo H Virchows Arch. 2024; 484(6):995-1003.

PMID: 38683251 PMC: 11186860. DOI: 10.1007/s00428-024-03810-y.